Beta-2 microglobulin as a biomarker for peripheral artery disease
Inventors
Cooke, John • Fung, Eric T. • Kimura, Eiichiro
Assignees
Ajinomoto Co Inc • Leland Stanford Junior University • Aspira Womens Health Inc
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-7867719-B2
Publication Date
2011-01-11
Expiration Date
Abstract
The present invention provides β2 microglobulin as a biomarker for qualifying or assessing peripheral artery disease in a subject.
Core Innovation
The disclosed methods use ̢-microglobulin measured in a subject’s biological sample to qualify peripheral artery disease status by correlating the measurement with peripheral artery disease versus non-peripheral artery disease. A separate method measures ̢-microglobulin in samples collected at two different times and compares the measurements to determine the course of peripheral artery disease.
The provided partial content also identifies cystatin C and lysozyme as additional biomarkers and describes blood, plasma, or serum samples, immunoassay or mass spectrometry measurement, and software-based classification as contemplated implementations. The background section itself is not included in the supplied content, so the problem stated there is not explicitly described in the patent material provided for this summary.
Claims Coverage
The relevant claims include two independent claims: one for qualifying peripheral artery disease status and one for determining its course.
Qualifying peripheral artery disease status
Measuring ̢-microglobulin in a biological sample from the subject and correlating the measurement or measurements with peripheral artery disease versus non-peripheral artery disease.
Determining the course of peripheral artery disease
Measuring ̢-microglobulin in biological samples from the subject at a first time and a second time, comparing the measurements, and using the comparative measurements to determine the course of the peripheral artery disease.
The independent claims cover using ̢-microglobulin measurements to classify peripheral artery disease status and comparing measurements taken at different times to determine disease course.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Qualifying a subject’s peripheral artery disease status by correlating ̢-microglobulin measurements with peripheral artery disease versus non-peripheral artery disease.
Determining the course of peripheral artery disease by comparing ̢-microglobulin measurements taken from a subject at two different times.
Interested in licensing this patent?